



## **SOPHiA GENETICS to Attend and Host Investor Meetings at the J.P. Morgan 50th Annual Global Technology, Media, and Communications Conference**

April 27, 2022

BOSTON and LAUSANNE, Switzerland, April 27, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today announced CFO, Ross Muken will attend the upcoming J.P. Morgan 50<sup>th</sup> Annual Global Technology, Media, and Communications Conference in Boston, Massachusetts on May 24. Management and IR will also host several meetings with investors at the conference. To coordinate a meeting, please contact Jennifer Pottage, Head of Investor Relations at [jpottage@sophiagenetics.com](mailto:jpottage@sophiagenetics.com).

### **About SOPHiA GENETICS**

SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by over 790 hospital, laboratory, and biopharma institutions globally. For more information, visit [SOPHiAGENETICS.COM](https://sophiagenetics.com), or connect on [Twitter](#), [LinkedIn](#) and [Instagram](#). **Where others see data, we see answers.**

### **Investor Contact:**

Jennifer Pottage  
Head of Investor Relations  
[jpottage@sophiagenetics.com](mailto:jpottage@sophiagenetics.com)

### **Media Contact:**

Eliza Bamonti  
Director of Public Relations  
[Ebamonti@sophiagenetics.com](mailto:Ebamonti@sophiagenetics.com)